Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 165

1.

Weighing the evidence for pharmacological treatment interventions in mild COPD; a narrative perspective.

Singh D, D'Urzo AD, Donohue JF, Kerwin EM.

Respir Res. 2019 Jul 8;20(1):141. doi: 10.1186/s12931-019-1108-9. Review.

2.

Cardiovascular safety of revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy of chronic obstructive pulmonary disease: Evaluation in phase 3 clinical trials.

Donohue JF, Feldman G, Sethi S, Barnes CN, Pendyala S, Bourdet D, Crater G.

Pulm Pharmacol Ther. 2019 May 29:101808. doi: 10.1016/j.pupt.2019.101808. [Epub ahead of print]

3.

Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary disease.

Donohue JF, Kerwin E, Sethi S, Haumann B, Pendyala S, Dean L, Barnes CN, Moran EJ, Crater G.

Respir Med. 2019 Jul;153:38-43. doi: 10.1016/j.rmed.2019.05.010. Epub 2019 May 23.

PMID:
31150963
4.

Aclidinium bromide in fixed-dose combination with formoterol fumarate in the management of COPD: an update on the evidence base.

D'Urzo AD, Singh D, Donohue JF, Chapman KR.

Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466619850725. doi: 10.1177/1753466619850725.

5.

Prevalence and factors associated with suboptimal peak inspiratory flow rates in COPD.

Ghosh S, Pleasants RA, Ohar JA, Donohue JF, Drummond MB.

Int J Chron Obstruct Pulmon Dis. 2019 Mar 1;14:585-595. doi: 10.2147/COPD.S195438. eCollection 2019.

6.

Efficacy of aclidinium/formoterol 400/12 µg, analyzed by airflow obstruction severity, age, sex, and exacerbation history: pooled analysis of ACLIFORM and AUGMENT.

D'Urzo AD, Singh D, Donohue JF, Kerwin EM, Ribera A, Molins E, Chuecos F, Jarreta D, Gil EG.

Int J Chron Obstruct Pulmon Dis. 2019 Feb 26;14:479-491. doi: 10.2147/COPD.S185502. eCollection 2019.

7.

Use of a Cross-Sectional Survey in the Adult Population to Characterize Persons at High-Risk for Chronic Obstructive Pulmonary Disease.

Pleasants RA, Heidari K, Ohar J, Donohue JF, Lugogo N, Richard CL, Kanotra S, Mannino DM, Kraft M, Liao W, Strange C.

Healthcare (Basel). 2019 Jan 18;7(1). pii: E12. doi: 10.3390/healthcare7010012.

8.

Health-Related Quality of Life Improvements in Moderate to Very Severe Chronic Obstructive Pulmonary Disease Patients on Nebulized Glycopyrrolate: Evidence from the GOLDEN Studies.

Ferguson GT, Kerwin EM, Donohue JF, Ganapathy V, Tosiello RL, Bollu VK, Rajagopalan K.

Chronic Obstr Pulm Dis. 2018 Jun 6;5(3):193-207. doi: 10.15326/jcopdf.5.3.2017.0178.

9.

Satisfaction with the Use of eFlow Closed-System Nebulizer in Patients with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: Findings from a Long-Term Safety Study.

Kerwin EM, Donohue JF, Ferguson GT, Ganapathy V, Ozol-Godfrey A, Rajagopalan K.

J Aerosol Med Pulm Drug Deliv. 2019 Feb;32(1):24-33. doi: 10.1089/jamp.2018.1477. Epub 2018 Nov 17.

PMID:
30457433
10.
11.

Long-term health-related quality-of-life and symptom response profiles with arformoterol in COPD: results from a 52-week trial.

Donohue JF, Bollu VK, Stull DE, Nelson LM, Williams VS, Stensland MD, Hanania NA.

Int J Chron Obstruct Pulmon Dis. 2018 Feb 5;13:499-508. doi: 10.2147/COPD.S141729. eCollection 2018.

12.

Correlations between FEV1 and patient-reported outcomes: A pooled analysis of 23 clinical trials in patients with chronic obstructive pulmonary disease.

Donohue JF, Jones PW, Bartels C, Marvel J, D'Andrea P, Banerji D, Morris DG, Patalano F, Fogel R.

Pulm Pharmacol Ther. 2018 Apr;49:11-19. doi: 10.1016/j.pupt.2017.12.005. Epub 2017 Dec 19. Review.

PMID:
29277690
14.
15.

Erratum to: A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease.

Reisner C, Fabbri LM, Kerwin EM, Fogarty C, Spangenthal S, Rabe KF, Ferguson GT, Martinez FJ, Donohue JF, Darken P, St Rose E, Orevillo C, Strom S, Fischer T, Golden M, Dwivedi S.

Respir Res. 2017 Aug 21;18(1):158. doi: 10.1186/s12931-017-0638-2. No abstract available.

16.

Corrigendum to "A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD" [Respir. Med. 120 November 2016 16-24].

Tashkin DP, Martinez FJ, Rodriguez-Roisin R, Fogarty C, Gotfried M, Denenberg M, Gottschlich G, Donohue JF, Orevillo C, Darken P, St Rose E, Strom S, Fischer T, Golden M, Reisner C.

Respir Med. 2017 Aug;129:164. doi: 10.1016/j.rmed.2017.06.011. Epub 2017 Jun 30. No abstract available.

17.

Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with chronic obstructive pulmonary disease.

Hanania NA, Tashkin DP, Kerwin EM, Donohue JF, Denenberg M, O'Donnell DE, Quinn D, Siddiqui S, Orevillo C, Maes A, Reisner C.

Respir Med. 2017 May;126:105-115. doi: 10.1016/j.rmed.2017.03.015. Epub 2017 Mar 12.

18.
19.

Comparative efficacy of long-acting β2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis.

Donohue JF, Betts KA, Du EX, Altman P, Goyal P, Keininger DL, Gruenberger JB, Signorovitch JE.

Int J Chron Obstruct Pulmon Dis. 2017 Jan 19;12:367-381. doi: 10.2147/COPD.S119908. eCollection 2017. Review.

20.

Tadalafil therapy for sarcoidosis-associated pulmonary hypertension.

Ford HJ, Baughman RP, Aris R, Engel P, Donohue JF.

Pulm Circ. 2016 Dec;6(4):557-562. doi: 10.1086/688775.

21.

A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease.

Reisner C, Fabbri LM, Kerwin EM, Fogarty C, Spangenthal S, Rabe KF, Ferguson GT, Martinez FJ, Donohue JF, Darken P, St Rose E, Orevillo C, Strom S, Fischer T, Golden M, Dwivedi S.

Respir Res. 2017 Jan 6;18(1):8. doi: 10.1186/s12931-016-0491-8. Erratum in: Respir Res. 2017 Aug 21;18(1):158.

22.

Health Status of Patients with Moderate to Severe COPD after Treatment with Nebulized Arformoterol Tartrate or Placebo for 1 Year.

Donohue JF, Ganapathy V, Bollu V, Stensland MD, Nelson LM.

Clin Ther. 2017 Jan;39(1):66-74. doi: 10.1016/j.clinthera.2016.11.021. Epub 2016 Dec 20.

PMID:
28011247
23.

A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD.

Tashkin DP, Martinez FJ, Rodriguez-Roisin R, Fogarty C, Gotfried M, Denenberg M, Gottschlich G, Donohue JF, Orevillo C, Darken P, St Rose E, Strom S, Fischer T, Golden M, Reisner C.

Respir Med. 2016 Nov;120:16-24. doi: 10.1016/j.rmed.2016.09.012. Epub 2016 Sep 17. Erratum in: Respir Med. 2017 Aug;129:164.

24.

Improving the Management of COPD in Women.

Jenkins CR, Chapman KR, Donohue JF, Roche N, Tsiligianni I, Han MK.

Chest. 2017 Mar;151(3):686-696. doi: 10.1016/j.chest.2016.10.031. Epub 2016 Nov 2. Review.

25.

Long-term safety of aclidinium bromide/formoterol fumarate fixed-dose combination: Results of a randomized 1-year trial in patients with COPD.

Donohue JF, Soong W, Wu X, Shrestha P, Lei A.

Respir Med. 2016 Jul;116:41-8. doi: 10.1016/j.rmed.2016.05.007. Epub 2016 May 7.

26.

A retrospective study of two populations to test a simple rule for spirometry.

Ohar JA, Yawn BP, Ruppel GL, Donohue JF.

BMC Fam Pract. 2016 Jun 4;17:65. doi: 10.1186/s12875-016-0467-2.

27.

Another Choice for Prevention of COPD Exacerbations.

Donohue JF.

N Engl J Med. 2016 Jun 9;374(23):2284-6. doi: 10.1056/NEJMe1604444. Epub 2016 May 15. No abstract available.

PMID:
27181835
28.

Dual therapy strategies for COPD: the scientific rationale for LAMA + LABA.

Cohen JS, Miles MC, Donohue JF, Ohar JA.

Int J Chron Obstruct Pulmon Dis. 2016 Apr 15;11:785-97. doi: 10.2147/COPD.S54513. eCollection 2016. Review.

29.

Efficacy and safety of ipratropium bromide/albuterol compared with albuterol in patients with moderate-to-severe asthma: a randomized controlled trial.

Donohue JF, Wise R, Busse WW, Garfinkel S, Zubek VB, Ghafouri M, Manuel RC, Schlenker-Herceg R, Bleecker ER.

BMC Pulm Med. 2016 Apr 30;16(1):65. doi: 10.1186/s12890-016-0223-3.

30.

The association of lung function and St. George's respiratory questionnaire with exacerbations in COPD: a systematic literature review and regression analysis.

Martin AL, Marvel J, Fahrbach K, Cadarette SM, Wilcox TK, Donohue JF.

Respir Res. 2016 Apr 16;17:40. doi: 10.1186/s12931-016-0356-1. Review.

31.

Magnitude of umeclidinium/vilanterol lung function effect depends on monotherapy responses: Results from two randomised controlled trials.

Donohue JF, Singh D, Munzu C, Kilbride S, Church A.

Respir Med. 2016 Mar;112:65-74. doi: 10.1016/j.rmed.2016.01.001. Epub 2016 Jan 7.

32.

Inhaled Umeclidinium in COPD Patients: A Review and Meta-Analysis.

Pleasants RA, Wang T, Gao J, Tang H, Donohue JF.

Drugs. 2016 Mar;76(3):343-61. doi: 10.1007/s40265-015-0532-5. Review.

PMID:
26755180
34.

Low Doses of Long-Acting β-Agonists/Long-Acting Muscarinic Agents with Large Effects. The FLIGHT Study.

Donohue JF.

Am J Respir Crit Care Med. 2015 Nov 1;192(9):1028-30. doi: 10.1164/rccm.201507-1442ED. No abstract available.

PMID:
26517413
35.

Dual bronchodilator therapy with aclidinium bromide/formoterol fumarate for chronic obstructive pulmonary disease.

D'Urzo T, Donohue JF, Price D, Miravitlles M, Kerwin E.

Expert Rev Respir Med. 2015 Oct;9(5):519-32. doi: 10.1586/17476348.2015.1081065. Epub 2015 Aug 26. Review.

PMID:
26366803
36.

A re-evaluation of the role of inhaled corticosteroids in the management of patients with chronic obstructive pulmonary disease.

D'Urzo A, Donohue JF, Kardos P, Miravitlles M, Price D.

Expert Opin Pharmacother. 2015;16(12):1845-60. doi: 10.1517/14656566.2015.1067682. Review.

37.

Indacaterol vs tiotropium in COPD patients classified as GOLD A and B.

Mahler DA, Kerstjens HA, Donohue JF, Buhl R, Lawrence D, Altman P.

Respir Med. 2015 Aug;109(8):1031-9. doi: 10.1016/j.rmed.2015.05.012. Epub 2015 May 22.

38.

Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations.

Donohue JF, Worsley S, Zhu CQ, Hardaker L, Church A.

Respir Med. 2015 Jul;109(7):870-81. doi: 10.1016/j.rmed.2015.04.018. Epub 2015 May 8.

39.

The ATS Foundation. 10 Years Old and Powered to Grow.

Donohue JF, Neumann L.

Ann Am Thorac Soc. 2015 May;12(5):629-30. doi: 10.1513/AnnalsATS.201503-159ED. No abstract available.

PMID:
25965539
40.

The impact of treatment with indacaterol in patients with COPD: A post-hoc analysis according to GOLD 2011 categories A to D.

Kerstjens HA, Deslée G, Dahl R, Donohue JF, Young D, Lawrence D, Kornmann O.

Pulm Pharmacol Ther. 2015 Jun;32:101-8. doi: 10.1016/j.pupt.2015.02.008. Epub 2015 Mar 3.

41.

CXCR2 Antagonist MK-7123. A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease.

Rennard SI, Dale DC, Donohue JF, Kanniess F, Magnussen H, Sutherland ER, Watz H, Lu S, Stryszak P, Rosenberg E, Staudinger H.

Am J Respir Crit Care Med. 2015 May 1;191(9):1001-11. doi: 10.1164/rccm.201405-0992OC.

PMID:
25695403
42.

Effect of once-daily indacaterol maleate/mometasone furoate on exacerbation risk in adolescent and adult asthma: a double-blind randomised controlled trial.

Beasley RW, Donohue JF, Mehta R, Nelson HS, Clay M, Moton A, Kim HJ, Hederer BM.

BMJ Open. 2015 Feb 3;5(2):e006131. doi: 10.1136/bmjopen-2014-006131.

43.

Umeclidinium/vilanterol combination inhaler efficacy and potential impact on current chronic obstructive pulmonary disease management guidelines.

Davidson JF, Donohue JF, Ohar JA.

Expert Opin Drug Saf. 2015 Feb;14(2):317-24. doi: 10.1517/14740338.2015.983898. Review.

PMID:
25598422
44.

Review of drug safety and efficacy of arformoterol in chronic obstructive pulmonary disease.

Loh CH, Donohue JF, Ohar JA.

Expert Opin Drug Saf. 2015 Mar;14(3):463-72. doi: 10.1517/14740338.2015.998196. Epub 2015 Jan 7. Review.

PMID:
25563342
45.

Systematic review comparing LABA, olodaterol, and indacaterol: limitations.

Donohue JF.

Int J Chron Obstruct Pulmon Dis. 2014 Dec 5;9:1331-3. doi: 10.2147/COPD.S74766. eCollection 2014. No abstract available.

46.

One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD.

Donohue JF, Hanania NA, Make B, Miles MC, Mahler DA, Curry L, Tosiello R, Wheeler A, Tashkin DP.

Chest. 2014 Dec;146(6):1531-1542. doi: 10.1378/chest.14-0117.

47.

Correlation of PROMIS scales and clinical measures among chronic obstructive pulmonary disease patients with and without exacerbations.

Irwin DE, Atwood CA Jr, Hays RD, Spritzer K, Liu H, Donohue JF, Leidy NK, Yount SE, DeWalt DA.

Qual Life Res. 2015 Apr;24(4):999-1009. doi: 10.1007/s11136-014-0818-1. Epub 2014 Oct 12.

48.

A simple rule to identify patients with chronic obstructive pulmonary disease who may need treatment reevaluation.

Sharafkhaneh A, Altan AE, Colice GL, Hanania NA, Donohue JF, Kurlander JL, Rodriguez-Roisin R, Altman PR.

Respir Med. 2014 Sep;108(9):1310-20. doi: 10.1016/j.rmed.2014.07.002. Epub 2014 Jul 14.

49.

Characterization of airway inflammation in patients with COPD using fractional exhaled nitric oxide levels: a pilot study.

Donohue JF, Herje N, Crater G, Rickard K.

Int J Chron Obstruct Pulmon Dis. 2014 Jul 16;9:745-51. doi: 10.2147/COPD.S44552. eCollection 2014.

Supplemental Content

Loading ...
Support Center